Teicoplanin: an alternative drug for the treatment of COVID-19?

被引：183

作者：

Baron, Sophie Alexandra ^{[1
]}

Devaux, Christian ^{[2
]}

Colson, Philippe ^{[1
]}

Raoult, Didier ^{[1
,3
]}

Rolain, Jean-Marc ^{[1
,3
]}

机构：

[1] Aix Marseille Univ, Fac Med & Pharm, AP HM, IRD,MEPHI, 19-21 Blvd Jean Moulin, F-13385 Marseille 05, France

[2] Aix Marseille Univ, Fac Med & Pharm, AP HM, IRD,VITROME, 19-21 Blvd Jean Moulin, F-13385 Marseille 05, France

[3] IHU Mediterranee Infect, 19-21 Blvd Jean Moulin, F-13385 Marseille 05, France

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2020年 / 55卷 / 04期

关键词：

SARS-CoV-2; Drug repurposing; Teicoplanin; COVID-19; ANTIBIOTICS;

D O I：

10.1016/j.ijantimicag.2020.105944

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

In December 2019, a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged from China causing pneumonia outbreaks, first in the Wuhan region of China and then spread worldwide because of its probable high transmission efficiency. Owing to the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the best tool to find a therapeutic solution. Chloroquine, remdesivir, lopinavir, ribavirin and ritonavir have shown efficacy to inhibit coronavirus in vitro. Teicoplanin, an antibiotic used to treat staphylococcal infections, previously showed efficacy to inhibit the first stage of the Middle East respiratory syndrome coronavirus (MERS-CoV) viral life cycle in human cells. This activity is conserved against SARS-Cov-2, thus placing teicoplanin as a potential treatment for patients with this virus. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

引用

页数：2

共 10 条

[1]

[Anonymous], PUBLICATION

[2]

[Anonymous], INT J ANTIMICROB AGE

[3] Chloroquine for the 2019 novel coronavirus SARS-CoV-2 [J].